Asset Manager

Updated:

FMB Research

FMB Research, founded by Franklin M. Berger in New York, is an investment company with an early-stage focus on biotech. Lean structure, no public AUM.

FMB Research

FMB Research is a US-based investment company headquartered in New York. It focuses on a Venture Capital strategy.

General information

Firm type

Generalist Asset Manager

Year founded

AUM

Undisclosed

Location

Region

North America

Country

United States

City

New York

Corporate office

600 Lexington Avenue, 30th Floor, New York, NY 10022, United States

Principals

Franklin M. Berger

Managing Director and Founder

Sector focus

Early StageBiotechHealthcare

Frequently asked questions

Who runs investment decisions at FMB Research?

Franklin M. Berger is the sole named principal, serving as Managing Director and Founder. He holds the CFA designation and maintains a professional network in Connecticut and New York.

What sectors does FMB Research focus on?

Public record shows a concentration in early-stage biotechnology. Berger's relationship with Atea Pharmaceuticals — a clinical-stage antiviral company — and his role on the Brain Tumor Biotech Center Investment Advisory Board point to healthcare as the primary focus.

Is FMB Research structured as a family office or a pooled investment vehicle?

FMB Research is an investment company, not a registered family office or fund. It does not appear to raise external capital, and likely operates solely on the founder's balance sheet.

How does FMB Research source deal flow?

Deal sourcing appears driven by Berger's professional network, including his relationship with Atea Pharmaceuticals CEO Jean-Pierre Sommadossi and advisory board connections with investors like Peter Boockvar.

What is the size of FMB Research's investment portfolio?

No AUM or deployment figures are publicly disclosed. FMB Research does not publish financial statements, raise institutional capital, or report holdings, leaving portfolio scale unknown.

Does FMB Research participate in fund commitments or only direct deals?

Based on available data, FMB Research appears oriented toward direct investments, such as its stake in Atea Pharmaceuticals. No evidence of multi-manager, fund-of-funds, or secondaries activity exists in the public record.

Where does FMB Research maintain offices?

The firm's headquarters are at 600 Lexington Avenue, 30th Floor, New York, NY. No additional office locations are disclosed.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on asset managers?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo